B7-33: molecular data, studies & sources

Molecular formula, weight & structure

Registered clinical trials

Studies registered on ClinicalTrials.gov that list B7-33 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received B7-33, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

1. Preclinical / laboratory research

   The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.

   Alam F, Gaspari TA, Kemp-Harper BK et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023

   PMID 36753958 · DOI: 10.1016/j.biopha.2023.114370

2. Research publication · design requires review

   B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin).

   Marshall SA, O'Sullivan K, Ng HH et al. · European journal of pharmacology · 2017

   PMID 28478069 · DOI: 10.1016/j.ejphar.2017.05.005

3. Preclinical / laboratory research

   B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.

   Devarakonda T, Mauro AG, Guzman G et al. · Journal of the American Heart Association · 2020

   PMID 32295457 · DOI: 10.1161/JAHA.119.015748

4. Research publication · design requires review

   Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation.

   Welch NG, Mukherjee S, Hossain MA et al. · ACS applied materials & interfaces · 2019

   PMID 31713411 · DOI: 10.1021/acsami.9b17859

B7-33 supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles